Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526075 | 1.00 | GRK2 (0.35) | GRK2P2RX7ALDH1A1DRD4SIGMAR1 | |
| SCHEMBL19805924 | 0.86 | SMN1; SMN2 (0.37) | GRK2P2RX7ALDH1A1DRD4SIGMAR1 | |
| SCHEMBL20985705 | 0.85 | SDHB (0.40) | GRK2P2RX7ALDH1A1DRD4SIGMAR1 | |
| SCHEMBL20985672 | 0.77 | SDHB (0.37) | GRK2P2RX7DRD4SIGMAR1ROCK2 | |
| SCHEMBL30526073 | 0.77 | SDHB (0.37) | GRK2P2RX7DRD4SIGMAR1ROCK2 | |
| SCHEMBL29976343 | 0.76 | SMN1; SMN2 (0.33) | GRK2P2RX7ALDH1A1DRD4SIGMAR1 | |
| SCHEMBL19806011 | 0.76 | SMN1; SMN2 (0.33) | GRK2P2RX7ALDH1A1DRD4SIGMAR1 | |
| SCHEMBL29976175 | 0.75 | MAPK14 (0.32) | P2RX7 | |
| SCHEMBL19805939 | 0.75 | MAPK14 (0.32) | P2RX7 | |
| SCHEMBL23897356 | 0.74 | GRK2 (0.43) | GRK2P2RX7ALDH1A1ROCK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| WO-2018014802-A1 | APOPTOSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | GRK2 3248/4885P2RX7 4784/4885ALDH1A1 550/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | GRK2 3248/4885P2RX7 4784/4885ALDH1A1 550/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | GRK2 3248/4885P2RX7 4784/4885ALDH1A1 550/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | GRK2 3248/4885P2RX7 4784/4885ALDH1A1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.